GLP-1 in Hot Weather: Summer Storage Solutions
Protect your GLP-1 medication from heat damage during summer. Storage temperature guidelines, travel cooling solutions, and signs your semaglutide or tirzepatide may be compromised.
More on Storage & Travel
Heat Is the Enemy
GLP-1 medications are protein-based and heat-sensitive. A car interior can reach 150F+ on a summer day, rapidly denaturing the active ingredient. Even brief heat exposure can reduce medication effectiveness. Prevention is far easier than replacing compromised medication.
Temperature Guidelines by Medication
Semaglutide (Ozempic/Wegovy)
- Unopened: Refrigerate 36-46F (2-8C)
- In use: Room temp below 86F (30C) up to 56 days
- Never freeze: Freezing destroys the protein
- Protect from light: Keep in original packaging
Tirzepatide (Mounjaro/Zepbound)
- Unopened: Refrigerate 36-46F (2-8C)
- In use: Room temp below 86F (30C) up to 21 days
- Never freeze: Freezing destroys the protein
- Single-dose pens: Use once and discard
Summer Survival Strategies
Never Leave in a Vehicle
This is the number one cause of GLP-1 medication heat damage. Even on a mild 80F day, car interior temperatures can exceed 120F within 20 minutes. On 100F+ days, temperatures can reach 170F. Always take your medication with you. If you must leave it briefly, place in an insulated cooling case in the trunk (cooler than the cabin) and retrieve as quickly as possible.
Use a FRIO Cooling Wallet
FRIO wallets use evaporative cooling technology to keep medications below 79F (26C) for 45+ hours. They are activated by soaking in water for a few minutes and require no ice or electricity. Lightweight and reusable, they are ideal for daily carry in hot climates. Available in sizes for 1-2 pens at most pharmacies and online retailers.
Home Storage During Power Outages
During power outages in summer, a refrigerator maintains temperature for approximately 4 hours if unopened. If the outage will be longer, transfer medication to a cooler with ice packs, ensuring a towel barrier between medication and ice. Monitor temperature with a thermometer. If your in-use pen stays below 86F, it remains usable within its out-of-refrigerator time limit.
Outdoor Activities and Beach Days
If you need medication with you at the beach, pool, or outdoor event, use an insulated cooler bag with a frozen gel pack. Keep the cooler in shade, never in direct sun. A small soft-sided insulated lunch bag with one frozen gel pack can maintain safe temperatures for 4-6 hours. Avoid leaving the cooler bag in sand or on hot surfaces.
Heat and Hydration: Double Risk
Summer heat creates a double challenge for GLP-1 users: medication storage AND personal hydration. GLP-1 medications reduce appetite and thirst cues, making dehydration more likely in hot weather. Combined with sweating, the risk of heat-related illness increases.
Increase Fluid Intake by 50% in Summer
If your baseline is 64 ounces daily, aim for 96+ ounces during hot weather. Add electrolytes to at least 1-2 servings daily. Set hourly hydration reminders, as thirst cues are suppressed by GLP-1 therapy. See our electrolyte guide for summer-specific recommendations.
Recognize Heat Illness Signs Early
GLP-1 users may be more susceptible to heat exhaustion due to baseline dehydration risk. Warning signs include excessive sweating followed by absent sweating, rapid pulse, nausea, headache, dizziness, confusion, and muscle cramps. Move to a cool area, hydrate, and seek medical attention if symptoms do not improve within 30 minutes.
Medical Disclaimer
This article is for informational purposes only. Always follow the specific storage instructions on your medication packaging. If you suspect your medication has been heat-damaged, contact your pharmacy for a replacement. Do not inject medication that appears cloudy, discolored, or contains particles.
Frequently Asked Questions
What temperature range is safe for GLP-1 medications?
Unopened GLP-1 pens should be refrigerated at 36-46F (2-8C). Once in use, semaglutide (Ozempic/Wegovy) can be stored at room temperature below 86F (30C) for up to 56 days. Tirzepatide (Mounjaro/Zepbound) can be stored at room temperature below 86F (30C) for up to 21 days. Never freeze, and never expose to temperatures above 86F. Direct sunlight also degrades the medication.
Can I use my GLP-1 pen if it was left in a hot car?
If your medication was exposed to temperatures above 86F (30C), it may have lost effectiveness. Semaglutide and tirzepatide are proteins that denature (unfold and become inactive) at high temperatures. A pen left in a car on a 90F day can reach internal temperatures of 130F+ within 30 minutes. When in doubt, use a new pen. Do not inject medication that appears cloudy, discolored, or has particles.
What are the best cooling cases for GLP-1 travel?
Medical-grade cooling cases maintain temperatures between 36-77F for 12-48 hours. Options include FRIO evaporative cooling wallets (reusable, no ice needed, activated with water), insulated medication pouches with ice packs, and electronic cooling cases for extended trips. Avoid placing medication directly against ice packs, as freezing is equally damaging. A thin barrier between the medication and cold source is essential.
How can I tell if my GLP-1 medication has been heat-damaged?
Visual signs of heat damage include cloudiness (solution should be clear), particles or floaters in the solution, discoloration (should be colorless to slightly yellow), and leaking from the pen. However, medication can lose potency from heat exposure without visible changes. If you suspect heat exposure, the safest approach is to discard and use a new pen. Using degraded medication means you may not receive the full dose.
Stay Cool, Stay on Track
Our team can help with medication replacements and summer management strategies for your GLP-1 therapy.
Consult with a ProviderSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).